2. GPCR/G Protein Neuronal Signaling
  3. mAChR
  4. Scopolamine butylbromide

Scopolamine butylbromide  (Synonyms: Hyoscine butylbromide; (-)-Scopolamine butylbromide; Butylscopolamine bromide)

Cat. No.: HY-N0340 Purity: 99.04%
COA
SDS
Handling Instructions Technical Support

Scopolamine butylbromide (Hyoscine butylbromide) is an orally active anticholinergic agent and spasmolytic. Scopolamine butylbromide binds with high affinity to rat cardiac M2 (Ki 83 nmol/L), hM2 (Ki 233 nmol/L), rat intestinal M3 (Ki 290 nmol/L) and hM3 (Ki 643 nmol/L) muscarinic receptors. Scopolamine butylbromide exerts a dose-dependent antagonistic effect on Carbachol-induced gastrointestinal smooth muscle spasm. Scopolamine butylbromide can be used for the research of abdominal colic and pain associated with gastrointestinal spasm, functional abdominal pain, chronic gastropathy and gastric ulcer.

For research use only. We do not sell to patients.

Scopolamine butylbromide

Scopolamine butylbromide Chemical Structure

CAS No. : 149-64-4

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
100 mg In-stock
500 mg In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Scopolamine butylbromide:

Scopolamine butylbromide Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Scopolamine butylbromide

View All mAChR Isoform Specific Products:

View All Isoforms
mAChR1 mAChR2 mAChR3 mAChR4 mAChR5

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Scopolamine butylbromide (Hyoscine butylbromide) is an orally active anticholinergic agent and spasmolytic. Scopolamine butylbromide binds with high affinity to rat cardiac M2 (Ki 83 nmol/L), hM2 (Ki 233 nmol/L), rat intestinal M3 (Ki 290 nmol/L) and hM3 (Ki 643 nmol/L) muscarinic receptors. Scopolamine butylbromide exerts a dose-dependent antagonistic effect on Carbachol-induced gastrointestinal smooth muscle spasm. Scopolamine butylbromide can be used for the research of abdominal colic and pain associated with gastrointestinal spasm, functional abdominal pain, chronic gastropathy and gastric ulcer[1][2].

IC50 & Target[1]

mAChR2

83 (rats) nM (Ki)

mAChR3

290 (rats) nM (Ki)

hM2

233 nM (Ki)

hM3

643 nM (Ki)

In Vitro

Scopolamine butylbromide binds with high affinity to rat cardiac M2 (Ki 83 nmol/L), hM2 (Ki 233 nmol/L), rat intestinal M3 (Ki 290 nmol/L) and hM3 (Ki 643 nmol/L) muscarinic receptors[1].
Scopolamine butylbromide specifically inhibits acetylcholine-induced contraction of isolated guinea pig ileum, with a pA2 value of 7.8; it also slightly inhibits histamine-induced contraction, with a pA2 value of 4.6[1].
Scopolamine butylbromide inhibits the contraction of isolated guinea pig colon induced by acetylcholine, transmural stimulation and pelvic nerve stimulation, with ID50 values of 8.13 × 10-8 mol/L, 1.15 × 10-7 mol/L and 2.54 × 10-7 mol/L, respectively. It also reduces acetylcholine release from stimulated nerves[1].
Scopolamine (0.1-800 μg/mL) butylbromide inhibits transmural stimulation-induced contraction and pressure-induced peristalsis of isolated guinea pig ileum at concentrations of 0.1-0.6 μg/mL and 4-6 μg/mL; however, due to limited tissue penetration, a dose of 600-800 μg/mL is required when administered via the mucosa[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Scopolamine butylbromide Related Antibodies
In Vivo

Scopolamine (intravenous injection) butylbromide exhibits a dose-dependent antagonistic effect on carbachol-induced gastrointestinal smooth muscle spasm in anesthetized rats[1].
Scopolamine (0.1-30 mg/kg; p.o.; single administration) butylbromide displaces ≥50% of the radioligand bound to muscarinic receptors in rat duodenal smooth muscle at doses of 0.1-3.0 mg/kg, whereas a dose of ≥30 mg/kg is required to achieve similar displacement in myocardium[1].
Scopolamine (3.0 μg/kg; intraduodenal administration; single dose) butylbromide and (0.25-50 mg/kg; intravenous injection; single dose) inhibits spontaneous and electrical stimulation-induced duodenal motility in anesthetized dogs[1].
Scopolamine (intravenous injection) butylbromide reduces pelvic nerve-induced colonic contractions in anesthetized guinea pigs in a dose-dependent manner, with an ED50 of 26 μg/kg and a relative potency of 16.4[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: anaesthetized[1]
Dosage: Not specified
Administration: i.v.; single dose
Result: Antagonized carbachol-induced increased gut tone dose-dependently across all GI tract sections.
Exhibited the lowest ID50 (highest potency) in the gastric antrum and the highest ID50 (lowest potency) in the rectum.
Animal Model: unspecified strain[1]
Dosage: 0.1 mg/kg; 3.0 mg/kg; 30 mg/kg
Administration: p.o.; single dose
Result: Caused ≥50% displacement of specifically bound radioligand from duodenal smooth muscle at 0.1-3.0 mg/kg.
Required a much higher dose (≥30 mg/kg) to induce displacement in heart muscle.
Showed a biphasic displacement curve for duodenal smooth muscle.
Animal Model: anaesthetized[1]
Dosage: 3.0 μg/kg (intraduodenal); 0.25 mg/kg (i.v.); 50 mg/kg (i.v.)
Administration: intraduodenal; single dose; i.v.; single dose
Result: Inhibited spontaneous and electrically stimulated duodenum motility at 3.0 μg/kg (intraduodenal).
Inhibited 60-100% of duodenum motility at 0.25-50 mg/kg (i.v.).
Clinical Trial
Molecular Weight

440.37

Formula

C21H30BrNO4
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

C[N+]1([C@H]2[C@@H](O3)[C@@H]3[C@@H]1C[C@H](OC([C@@H](C4=CC=CC=C4)CO)=O)C2)CCCC.[Br-]
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

DMSO : ≥ 90 mg/mL (204.37 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.2708 mL 11.3541 mL 22.7082 mL
5 mM 0.4542 mL 2.2708 mL 4.5416 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.25 mg/mL (5.11 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.25 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.25 mg/mL (5.11 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.25 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.97%

SDS (396 KB)

COA (256 KB) HNMR (143 KB) LCMS (265 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.2708 mL 11.3541 mL 22.7082 mL 56.7704 mL
5 mM 0.4542 mL 2.2708 mL 4.5416 mL 11.3541 mL
10 mM 0.2271 mL 1.1354 mL 2.2708 mL 5.6770 mL
15 mM 0.1514 mL 0.7569 mL 1.5139 mL 3.7847 mL
20 mM 0.1135 mL 0.5677 mL 1.1354 mL 2.8385 mL
25 mM 0.0908 mL 0.4542 mL 0.9083 mL 2.2708 mL
30 mM 0.0757 mL 0.3785 mL 0.7569 mL 1.8923 mL
40 mM 0.0568 mL 0.2839 mL 0.5677 mL 1.4193 mL
50 mM 0.0454 mL 0.2271 mL 0.4542 mL 1.1354 mL
60 mM 0.0378 mL 0.1892 mL 0.3785 mL 0.9462 mL
80 mM 0.0284 mL 0.1419 mL 0.2839 mL 0.7096 mL
100 mM 0.0227 mL 0.1135 mL 0.2271 mL 0.5677 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Scopolamine butylbromide Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Scopolamine butylbromide149-64-4Hyoscine butylbromide (-)-Scopolamine butylbromideButylscopolaminemAChRMuscarinic acetylcholine receptorgastrointestinal tissuehuman muscarinic M3 receptorganglion blockermuscarinic receptor antagonisthuman muscarinic M2 receptorguinea pig ileumguinea pig colonirritable bowel syndromeulcus ventriculihuman nicotinic acetylcholine receptorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Scopolamine butylbromide
Cat. No.:
HY-N0340
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (396 KB) Français - FR (396 KB) Deutsch - DE (396 KB) Norwegian - NO (396 KB) Español - ES (396 KB) Swedish - SV (396 KB) Italian - IT (396 KB) Korean - KR (396 KB) Portuguese - PT (396 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.